News and Events

Deep and durable clinical response to intratumoral injection of toll-like receptor 9 (TLR9) agonist CMP-001

1 May 2020

Intratumoral (IT) injection of CMP-001, a CpG-A TLR9 agonist packaged within a virus-like particle, is designed to activate tumor-associated plasmacytoid dendritic cells, inducing an interferon-rich tumor microenvironment and anti-tumor CD8+ T cell responses. According to this recent study, IT CMP-001 alone and in combination with pembrolizumab appears well tolerated, can reverse resistance to anti-PD-1 therapy, and can produce deep and durable clinical responses in patients with advanced melanoma.

Virtual biopsy using MRI radiomics for prediction of BRAF status in melanoma brain metastasis

29 April 2020

The aim of this recent study was to investigate the use of radiomics analysis for non-invasive identifcation of BRAF mutation in patients with melanoma brain metastases, based on conventional magnetic resonance imaging (MRI) data. The study concludes that radiomics-based noninvasive genetic characterization is feasible and should be further verifed using large prospective cohorts.

Advances in lymphoedema prevention, detection and management

29 April 2020

Secondary lymphoedema in the developed world is most commonly attributed to cancer treatment. The authors of his article review the current data surrounding lymphoedema initiatives, e.g. a prospective screening and a prospective surveillance model (PSM) for early diagnosis and intervention for the prevention and treatment of lymphoedema.